Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

clarkhealthcommunications

- PMLiVE

How smart spaces and real-time strategy transformed ASCO® 2025

Nick Bellomo, Director of Technology and Engagement, Inizio Medical ASCO® 2025 wasn’t just about oncology breakthroughs - it was also a showcase for how technology is redefining congress engagement. Supporting...

Inizio

- PMLiVE

The science is shifting in oncology: Are you ready to evolve with it?

Patty Zipfel, PhD, SVP, Scientific Strategy, Inizio Evoke. This year’s ASCO® meeting spotlighted a bold shift in oncology: the possibility of curing metastatic disease. A new trial design in metastatic...

Inizio

Reimagine health with Inizio.

At Inizio, we provide tailored, innovative solutions to help health and life sciences companies with their clinical development and commercialization journeys, maximizing patient access. Our experts guide you through each...

Inizio

- PMLiVE

Sanofi’s multiple myeloma candidate granted FDA orphan drug designation

More than 180,000 people worldwide are diagnosed with the disease every year

- PMLiVE

Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

Approximately 125 million people globally are living with some form of psoriasis

- PMLiVE

Are botanical drugs part of the future of medicine?

Botanical drugs are stepping into the space between traditional remedies and modern pharmaceuticals

Navigating NHS Market Access: Policy Change and Opportunity in England With Sarah Everest Ford

Navigating NHS Market Access: Policy Change and Opportunity in England

With the changes at NHS England and the publishing of the 10-Year Plan, there is a lot of talk of change in the NHS in England. But what do these...

Petauri Evidence

- PMLiVE

Gilead Sciences’ Biktarvy granted FDA approval for expanded HIV use

An estimated 1.2 million people in the US are currently living with the virus

- PMLiVE

FDA approves Apellis’ Empaveli for two rare kidney diseases

C3G and primary IC-MPGN are estimated to affect 5,000 people in the US

- PMLiVE

Trust and trends – proactive protection

To thrive in today’s communication ecosystem, we must tailor our messaging rationally and emotionally

- PMLiVE

Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

More than seven million people in the US are affected by the neurodegenerative disease

- PMLiVE

BMS granted FDA priority review for Breyanzi in marginal zone lymphoma

The disease accounts for approximately 7% of all non-Hodgkin lymphoma cases

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links